Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
Vincent Kompany claims it is "unacceptable" Man City had no fans at their Champions League tie at CSKA while the home side apparently did.
Teenagers are being tricked into sending inappropriate photographs through social media, police say.
June and Barry Steenkamp tell Good Morning Britain they accept the judge's decision but still do not believe Pistorius' version of events.